BIRC3 and cancer: Once in the nucleus, this protein increased the transcriptional activity of several genes associated with malignancy markers, including BIRC3 and ESR1. The changes in the expression of these genes were involved in the acquired resistance to anti-cancer drugs, doxorubicin and tamoxifen, respectively [4,5,6].